제6회 서울국제신약포럼 > Forum & Conference

본문 바로가기

파이낸셜뉴스 부산파이낸셜뉴스 블록포스트 가이드포스트 fn아이포커스 파이낸셜뉴스재팬 fnMICE fn이노에듀 fn투어


지난행사목록

본문

 

Jae-Hyun Kim
President/Korea Research Institute of Chemical Technology


1989 Ph.D, Korea Advanced Institute of Science and Technology / Chemistry
1981 Master, Korea Advanced Institute of Science and Technology / Chemistry
1979 Bachelor, Seoul National University / Chemistry Education 


2011 - President, KRICT
1983 - Professor, Kongju National University
2006 - 2010 President, Kongju National University
1998 - 2001 Vice President, Office of Planning, Kongju National University
1981 - 1983 Chief Official of Industrial Policy, Ministry of Science and Technology
1993 - 1994 Exchange Professor, University of Wisconsin at Madison
2005 - 2006 Member, Permanent Consulting Council of Nuri Project, 
Ministry of Education and Human Resources Development
2008 - 2010 Auditor, Korean Council of University Education
2001 - 2005 Member, Editorial Review Board of Journal of Chemistry education, 
American Chemical Society 
2002 - 2003 Chair, Editorial Review Board of Chemical Education, Korean Chemical Society
 
 
Dong-Ho Lee
CEO/Korea Drug Development Fund


2006 MBA, Korea University School of Business
1992 Ph.D., Department of Anesthesiology, Seoul National University School of Medicine, 
1979 M.D., Department of Anesthesiology, Seoul National University School of Medicine


Sep 2011 to present Korea Drug Development Fund (KDDF)
Chief Executive Officer at KDDF, government-initiated program for drug development that manages a total budget of US $1 billion
2007-2011 Korea National Enterprise for Clinical Trials (KoNECT)
Vice President at KoNECT, government supported organization that works to further improve Korea’s clinical trial infrastructure and develop the domestic pharmaceutical industry by serving as an international hub for clinical trials
2007 – Aug 2011 Asan Medical Center
Executive Director, Clinical trial center
Professor, Department of Clinical Pharmacology and Therapeutics
Professor, Department of Anesthesiology and Pain Medicine
Oct 2004 –May 2007 Samyang Corporation
Head (Executive Vice President), Pharmaceuticals Business Unit
1987 – 2001 Hanyang University School of Medicine
Professor, Department of Anesthesiology
1995 – 2001 Hanyang University Kuri Hospital
Chairman, Department of Anesthesiology
Director, Surgical intensive care unit
Director, Operating Theater
1993 – 1994 Yale University Hospital, Connecticut, USA
Visiting Professor, Department of Anesthesiology
 
 
Michel Goldman
Executive Director/Innovative Medicines Initiative

Michel Goldman is the Executive Director of the Innovative Medicines Initiative and a Professor of Immunology at the Université Libre de Bruxelles. Previously, Michel Goldman was Head of the Institute for Medical Immunology in Charleroi and a founder of the BioWin Health Cluster in Wallonia, Belgium. His scientific contributions in the field of vaccines, organ transplantation and the hypereosinophilic syndrome (a rare disease) were recognized by the clinical sciences award of the National Fund for Scientific Research (Belgium, 2000). In addition, Michel Goldman held the Spinoza chair at the University of Amsterdam (The Netherlands, 2001) and was made Doctor Honoris Causa by the Université of Lille (France, 2007).
He received MD and PhD degrees in Brussels University and was a fellow of the World Health Organization Immunology Research Centre in Geneva.
 
 
Boo-Hyun Yang
Patent Attorney/Zenith Patent & Law Firm


Yonsei University, Seoul, Korea
Master of Science in Biochemistry (particularly Enzymology), 1993

Sogang University, Seoul, Korea
Bachelor of Science in Biology, 1990


Zenith Patent & Law Firm, Seoul, Korea
Biotech/Chemistry Team Manager, 2005-Present
Current responsibilities include: 
1) Providing legal counseling particularly on patent practice; 
2) Drafting and translating patent specifications and claims related to biotechnology, chemistry, biochemistry and pharmaceuticals; 
3) Communicating with foreign associates and clients as well as domestic clients; 
4) Drafting, revising, negotiating and reviewing legal documents and/or agreements; 
5) Drafting responses for Office Actions from various Patent Offices such as KIPO and USPTO; 
7) Preparing and making presentations to existing and potential clients and foreign associates; and
Seshin Patent & Law Firm, Seoul, Korea 
Biotech/Chemistry Team Manager, 1999-2004
Doosan Technology Center of Doosan Co., Ltd., Gyeonggi-do, Korea
Researcher, 1994
 
 
Gary L. Geipel
Senior Director/Lilly Global Corporate Affairs for Lilly Oncology


Ph.D., Political Science, Columbia University, 1993. Dissertation topic: technology policy.
M.A., M.Phil., Political Science, Columbia University, 1987-88.
ITT International Fellow, Ludwig-Maximilians-Universität (Munich, Germany), 1984-85. Emphases: communications policy and international affairs.
A.B. summa cum laude, Journalism and International Relations, University of Southern California, 1984.


Senior Director, Global Oncology Corporate Affairs, Eli Lilly and Company (Indianapolis), 2012 to present. Corporate Affairs lead in the firm’s oncology business unit; created and leads PACE (www.PACENetwork.com) and coordinates strategy across communications, government affairs, advocacy- and professional-group relations, media relations, and other Corporate Affairs functions in key markets worldwide.
Senior Associate, National Institute for Public Policy (Fairfax, Virginia), 2003 to present. Occasional policy research on national-security issues.
Director, Corporate Affairs, Lilly Deutschland GmbH (Bad Homburg, Germany), 2009-11. Corporate Affairs lead in the German affiliate of Eli Lilly and Company; managed team of 30 professionals including all Corporate Affairs functions and Pricing, Reimbursement, and Access (PRA) responsibilities.
Director, Executive Communications, Eli Lilly and Company (Indianapolis), 2008-09, and Manager, Executive Communications, Eli Lilly and Company (Indianapolis), 2004-08. Principal writer for two successive CEOs, covering the full range of employee communications, investor relations, public-policy setting, and other business purposes; also significantly expanded CEOs’ media visibility through op-ed articles in The Wall Street Journal and other publications.
Vice President and Chief Operating Officer, Hudson Institute (Indianapolis), 2001-03. Responsibilities included project management, communications, strategic planning, human resources, and marketing for this not-for-profit policy research organization—in addition to research, writing, and public appearances on a wide range of policy issues.
Communications and Marketing Consultant, self-employed, 1999-2001. Principal client: Stamats Communications (Cedar Rapids, Iowa), the nation’s leading publisher of viewbooks and other marketing materials for private colleges and universities.
Deputy Communications Director and Midwest Field Director (Iowa Caucuses), Office of Vice President Dan Quayle and Quayle 2000, 1998-99.
Research Fellow, Senior Fellow and then Director of Research and Programs, Hudson Institute (Indianapolis), 1989-97.
Adjunct Faculty Member, Butler University (Indianapolis), Department of Political Science, 1993-97.
Analyst, MOSAIC Group (Tucson, Arizona), 1988-89. Responsibilities included contract research and the preparation of briefings and reports on technology policy.
Reporter, Business Week, Boston bureau, 1986.
Assistant Editor, East/West Network of in-flight publications (Los Angeles), 1984.
Reporter, Los Angeles Times, Washington and suburban Los Angeles bureaus, 1983.
 
 
Jei-Man Ryu
CEO/Shinpoong Pharmaceutical Ind Company


1975 - 1979College of Pharmacy, Seoul National University
Graduated with bachelar
1986 - 1988 Postgraduate School, Seoul National University
Graduated with M.S. degree
1990 - 1998 Postgraduate School, Seoul National University
Graduated with Ph.D. degree


1981 - 2009 Researcher and Manager of Research Laboratories in DongWha Pharmaceutical Ind. Company 
2009 – 2010 Director of Research & development in Jeil Pharmaceutical Ind. Company
2011 - CEO in Shinpoong Pharmaceutical Ind Company
 
 
Byung-Geon Rhee
President/Green Cross Holdings Corporation


- Doctor of Philosophy, Chemical Engineering and Biomedical Engineering 
Rice University 
- Master of Science, Chemical Engineering 
Seoul National University
- Bachelor of Science, Chemical Engineering
Seoul National University


2014 ~  President, Green Cross Holdings Corporation
2013 ~ Chairman, Korea Biotechnology Industry Organization 
2010 ~  Deputy Chairman, Korea Industrial Technology Association 
2010 ~ 2013 President, Green Cross Corporation
2002 President & CEO, Expression Genetics, Inc. (US)
1994 Head of Pharmaceutical Business Unit, Samyang Corporation
1987 Head of Safety Center, LG Research Institute
1986 Research Associate, University of Wisconsin
 
 
Suk-Kyu Lee
Ministry of Health and Welfare Director/Health Industry Promotion Division


1984: Sung Kyun Kwan University, Law Department, Seoul
1997: Indiana State University USA, Graduate School Master of Social Gerontology
2003-2004: visiting scholar of Gerontology Research Center, Simon Fraser University, Canada 


Director of International Affairs Division, Children Welfare Division, 
Health Insurance Rights Protection Division, Oral Health & Health Life Division, 
Welfare Benefits and Rights Protection Division at the Ministry of Health and Welfare
Writings:
“Korea Handbook on Health and Welfare: Dreaming of Mindful Welfare Society”, May 2014, Jisik Gonggam Publishing
 
 
Yo-Up Lim
Director of Future Technology Division/Ministry of Science, ICT and Future Planning


2003. ~ 2005. M.S. Thunderbird Graduate School of International Management, U.S


2009. ~ 2010. Director, Convergence Technology Division, Ministry of Education, Science and Technology(MEST) 
2010. ~ 2010. Director, e-Learning Support Division, MEST 
2011. ~ 2011. Director, Graduate School System Division, MEST
2011. ~ 2012 Director, Fundamental Research Division, MEST 
2012. ~ 2013. Institut Pasteur, France
2013. 2 ~ precent Director, Future Technology Division, Ministry of Science, ICT and Future Planning(MSIP)
 
 
Seok-Jin Chung
Director/Bio & Nano Technology Division in the Ministry of Trade, Industry and Energy


Seoul National University(B.A), Georgetown Univ.(M.A)


2011-2012 Director, Northeast Industry Cooperation Division Ministry of Knowledge Economy
2013- Director, Bio&Nano Technology Division Ministry of Trade, Industry & Energy
 
 
Jae-Du Ha
Director/Division of Drug Discovery Research Korea Research Institute of Chemical Technology


1980-1987 Pusan National University, B.S. Chemistry
1995-1999 The University of Alabama, Ph.D. Organic Chemistry


1987- Research Chemist, KRICT
1993-2005 Senior Researcher, KRICT 
2005- Principal Researcher, KRICT
2011- Director, Division of Drug Discovery Research, KRICT
2012- Adjunct Professor, Graduate School of New Drug Discovery and Development, ChungNam National University
 
 

첨부파일

서울특별시 서초구 강남대로 315, 파이낸셜뉴스빌딩 9층 | TEL. 02-6965-0016 | FAX. 02-6965-0000 | E-mail : info@fnmice.com
Copyright (c) fnMICE. All rights reserved.